150 related articles for article (PubMed ID: 38847773)
1. Comparative effects of calcitriol and calcimimetic on bone health in renal insufficiency.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Herencia C; López-Baltanás R; Jurado-Montoya D; García-Saez RM; Valdés-Díaz K; Martínez-Moreno JM; Santamaría R; Pendón-Ruiz de Mier MV; Rodelo-Haad C; Frazão JM; Felsenfeld AJ; Rodríguez M; Almadén Y; Muñoz-Castañeda JR
FASEB J; 2024 Jun; 38(11):e23726. PubMed ID: 38847773
[TBL] [Abstract][Full Text] [Related]
2. Calcimimetics maintain bone turnover in uremic rats despite the concomitant decrease in parathyroid hormone concentration.
Díaz-Tocados JM; Rodríguez-Ortiz ME; Almadén Y; Pineda C; Martínez-Moreno JM; Herencia C; Vergara N; Pendón-Ruiz de Mier MV; Santamaría R; Rodelo-Haad C; Casado-Díaz A; Lorenzo V; Carvalho C; Frazão JM; Felsenfeld AJ; Richards WG; Aguilera-Tejero E; Rodríguez M; López I; Muñoz-Castañeda JR
Kidney Int; 2019 May; 95(5):1064-1078. PubMed ID: 30878213
[TBL] [Abstract][Full Text] [Related]
3. Multiscale effects of the calcimimetic drug, etelcalcetide on bone health of rats with secondary hyperparathyroidism induced by chronic kidney disease.
Sharma S; Kumar S; Tomar MS; Chauhan D; Kulkarni C; Rajput S; Sadhukhan S; Porwal K; Guha R; Shrivastava A; Gayen JR; Kumar N; Chattopadhyay N
Bone; 2024 Aug; 185():117126. PubMed ID: 38777312
[TBL] [Abstract][Full Text] [Related]
4. A mathematical model of calcium and phosphorus metabolism in two forms of hyperparathyroidism.
Raposo JF; Pires A; Yokota H; Ferreira HG
Endocrine; 2012 Apr; 41(2):309-19. PubMed ID: 21874319
[TBL] [Abstract][Full Text] [Related]
5. Calcitriol Suppression of Parathyroid Hormone Fails to Improve Skeletal Properties in an Animal Model of Chronic Kidney Disease.
Newman CL; Tian N; Hammond MA; Wallace JM; Brown DM; Chen NX; Moe SM; Allen MR
Am J Nephrol; 2016; 43(1):20-31. PubMed ID: 26881752
[TBL] [Abstract][Full Text] [Related]
6. 22-oxacalcitriol suppresses secondary hyperparathyroidism without inducing low bone turnover in dogs with renal failure.
Monier-Faugere MC; Geng Z; Friedler RM; Qi Q; Kubodera N; Slatopolsky E; Malluche HH
Kidney Int; 1999 Mar; 55(3):821-32. PubMed ID: 10027919
[TBL] [Abstract][Full Text] [Related]
7. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
[TBL] [Abstract][Full Text] [Related]
8. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
Brandi L
Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
[TBL] [Abstract][Full Text] [Related]
9. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
Liu Y; Yang Q; Chen G; Zhou T
Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
[TBL] [Abstract][Full Text] [Related]
10. The calcimimetic AMG 641 abrogates parathyroid hyperplasia, bone and vascular calcification abnormalities in uremic rats.
Henley C; Davis J; Miller G; Shatzen E; Cattley R; Li X; Martin D; Yao W; Lane N; Shalhoub V
Eur J Pharmacol; 2009 Aug; 616(1-3):306-13. PubMed ID: 19470383
[TBL] [Abstract][Full Text] [Related]
11. Calcimimetics normalize the phosphate-induced stimulation of PTH secretion in vivo and in vitro.
Almaden Y; Rodriguez-Ortiz ME; Canalejo A; Cañadillas S; Canalejo R; Martin D; Aguilera-Tejero E; Rodríguez M
J Nephrol; 2009; 22(2):281-8. PubMed ID: 19384847
[TBL] [Abstract][Full Text] [Related]
12. Physiological doses of calcium regulatory hormones do not normalize bone cells in uraemic rats.
Szabó A; Freesmeyer MG; Abendroth K; Stein G; Rosivall L; El-Shakmak A; Ritz E
Eur J Clin Invest; 1999 Jun; 29(6):529-35. PubMed ID: 10354215
[TBL] [Abstract][Full Text] [Related]
13. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
[TBL] [Abstract][Full Text] [Related]
14. Outcomes of secondary hyperparathyroidism in chronic kidney disease and the direct costs of treatment.
Joy MS; Karagiannis PC; Peyerl FW
J Manag Care Pharm; 2007 Jun; 13(5):397-411. PubMed ID: 17605511
[TBL] [Abstract][Full Text] [Related]
15. Dynamics of skeletal resistance to parathyroid hormone in the rat: effect of renal failure and dietary phosphorus.
Bover J; Jara A; Trinidad P; Rodriguez M; Felsenfeld AJ
Bone; 1999 Sep; 25(3):279-85. PubMed ID: 10495131
[TBL] [Abstract][Full Text] [Related]
16. NF-κB activation contributes to parathyroid cell proliferation in chronic kidney disease.
Kan S; Zhang W; Mao J; Wang M; Ni L; Zhang M; Zhang Q; Chen J
J Nephrol; 2018 Dec; 31(6):941-951. PubMed ID: 30171599
[TBL] [Abstract][Full Text] [Related]
17. Effect of paricalcitol on mineral bone metabolism in kidney transplant recipients with secondary hyperparathyroidism.
Borrego Utiel FJ; Bravo Soto JA; Merino Pérez MJ; González Carmelo I; López Jiménez V; García Álvarez T; Acosta Martínez Y; Mazuecos Blanca MA
Nefrologia; 2015; 35(4):363-73. PubMed ID: 26306956
[TBL] [Abstract][Full Text] [Related]
18. Calcemic response to parathyroid hormone in renal failure: role of calcitriol and the effect of parathyroidectomy.
Rodriguez M; Felsenfeld AJ; Llach F
Kidney Int; 1991 Dec; 40(6):1063-8. PubMed ID: 1762307
[TBL] [Abstract][Full Text] [Related]
19. Paricalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease.
Ritter C; Miller B; Coyne DW; Gupta D; Zheng S; Brown AJ; Slatopolsky E
Kidney Int; 2017 Nov; 92(5):1217-1222. PubMed ID: 28750928
[TBL] [Abstract][Full Text] [Related]
20. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion.
Henley C; Yang Y; Davis J; Lu JY; Morony S; Fan W; Florio M; Sun B; Shatzen E; Pretorius JK; Richards WG; St Jean DJ; Fotsch C; Reagan JD
J Pharmacol Exp Ther; 2011 Jun; 337(3):681-91. PubMed ID: 21422163
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]